Never Miss a Breakthrough

Preclinical CAR T study in mouse models of pancreatic, kidney, and ovarian cancer testing a high-sensitivity CD70-targeting HLA-independent T cell receptor co-expressing CD80 and 4-1BBL. Demonstrates that heterogeneous, epigenetically regulated CD70 expression undetectable by conventional staining can be eliminated by these sensitive receptors, rescuing tumors that evade prototypic CAR T cells.

Preclinical study in mouse models of glioblastoma and ovarian cancer testing CAR T cells engineered to secrete an anti-VEGF single-chain variable fragment. Shows the secretion approach yields complete tumor elimination in 63 to 88% of glioblastoma mice versus 0 to 38% for conventional CAR T or CAR T combined with systemic anti-VEGF antibody.

Narrative review synthesizing hematologic CAR T cell and T cell engager experience for application to autoimmune disease. Argues that lessons from oncologic use, where CAR T cells require expansion, persistence, and antigen engagement, can guide therapy design in autoimmunity, where the goal shifts to interrupting pathogenic immune circuits and restoring tolerance.